Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$2.61

52W Range

$2.08 - $5.09

50D Avg

$2.61

200D Avg

$3.08

Market Cap

$144.19M

Avg Vol (3M)

$188.25K

Beta

0.04

Div Yield

-

ABOS Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

51

IPO Date

Jul 01, 2021

Website

ABOS Performance

ABOS Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-61.14M	$-45.24M	$61.57M
Net Income	$-52.37M	$-40.48M	$-181.68M
EBITDA	$-60.95M	$-45.07M	$61.58M
Basic EPS	$-1.08	$-1.00	$-9.06
Diluted EPS	$-1.08	$-1.00	$-9.06

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 12, 24 | 1:17 PM

Q2 24Aug 13, 24 | 11:17 AM

Q1 24May 14, 24 | 12:46 PM

Peer Comparison

Ticker	Company
XFOR	X4 Pharmaceuticals, Inc.
MREO	Mereo BioPharma Group plc
DAWN	Day One Biopharmaceuticals, Inc.
HOOK	HOOKIPA Pharma Inc.
TERN	Terns Pharmaceuticals, Inc.
INZY	Inozyme Pharma, Inc.
AMLX	Amylyx Pharmaceuticals, Inc.